Breast Cancer Screening, Breast Cancer Screening and Diagnosis
Conditions
Keywords
Breast cancer, Breast cancer screening, BRADS, Mammography, Dense breast, Breast imaging
Brief summary
This retrospective, observational study aims to evaluate how breast density affects the accuracy and outcomes of mammographic screening for breast cancer within the regional screening program "Prevenzione Serena". Breast density is an important factor because dense breast tissue can make it more difficult to detect breast cancer on a mammogram. Dense tissue and tumors both appear white on a mammogram, which may hide abnormalities and lead to missed cancers or false-positive results. Women aged 45 to 75 years who underwent routine mammographic screening at ASL CN2 between September 2023 and May 2024 will be included. Breast density will be classified using the BI-RADS system (categories A-D), and the study will assess whether women with dense breasts (categories C and D) experience higher rates of recalls for second-level examinations such as ultrasound, MRI, etc). The study also includes an internal validation of Insight BD, an automated breast-density measurement software used at ASL CN2. The software will be evaluated using a mammography phantom (to verify technical accuracy) and by comparing its BI-RADS density classifications with readings from two radiologists (one expert and one less experienced). This will help determine whether the software can support radiologists, especially in evaluating dense breast tissue. Additional factors such as menopausal status, family history of breast cancer, and hormone therapy will also be examined to understand how they relate to breast density and screening outcomes. The study aims to quantify the frequency of false-positive recalls-cases in which additional tests are recommended but cancer is not found-because these events can increase patient anxiety and healthcare workload. Ultimately, this research seeks to provide evidence that may inform future screening guidelines and support more personalized approaches, particularly for women with dense breasts.
Detailed description
This retrospective, monocentric, observational study investigates the impact of breast density on mammographic screening performance in the regional program "Prevenzione Serena," implemented at ASL CN2 (Piedmont, Italy). The primary objective is to evaluate the association between BI-RADS breast-density categories and the frequency of recalls for second-level diagnostic examinations among women aged 45-75 undergoing screening mammography between 25 September 2023 and 3 May 2024. Breast density is a known factor that can reduce the sensitivity of mammography. Dense fibroglandular tissue appears radiopaque and may mask suspicious lesions, leading to false-negative or false-positive examinations. Women with dense breasts (BI-RADS categories C-D) also have an independently increased risk of breast cancer. For these reasons, the study aims to characterize how breast density influences recall rates, diagnostic appropriateness, and overall screening performance in a real-world population. A secondary goal is the internal validation of Insight BD, an automated breast-density assessment software integrated into the Siemens Mammomat Revelation mammography system used at ASL CN2. The validation includes: 1. Technical validation using a dedicated mammographic phantom with known density values to determine measurement accuracy and repeatability; 2. Diagnostic validation through comparison between the BI-RADS density category assigned by the software and those assigned by two radiologists (one expert, one non-expert). The study will also examine associations between breast density and key clinical factors, including menopausal status, family history of breast cancer, and systemic hormone therapy. Furthermore, the frequency of false-positive recalls (additional testing without a final diagnosis of cancer) will be assessed, given their clinical, psychological, and organizational implications. The study aims to characterize density-related patterns in screening performance, quantify false-positive recalls, and contribute evidence to support future updates to breast-screening guidelines and potential personalized screening strategies, especially for women with dense breast tissue.
Interventions
No intervention is administered.
Sponsors
Study design
Eligibility
Inclusion criteria
* Women aged 45 to 75 years who participated in the "Prevenzione Serena" mammography screening program and underwent screening mammography at ASL CN2 between September 25, 2023, and May 3, 2024. * Signed informed consent or equivalent substitute declaration, when applicable.
Exclusion criteria
* Women with a history of mastectomy. * Women with breast implants. * Women with cardiac implantable devices, such as pacemakers or loop recorders. * Cases in which the Insight BD software cannot be applied due to compression thickness below 15 mm.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recall Rate for Second-Level Examinations by BI-RADS Breast Density Category | September 2023 - May 2024 | Percentage of women recalled for second-level diagnostic examinations among all women undergoing mammographic screening, calculated separately for each BI-RADS density category (A, B, C, D) and for the dichotomized groups A-B versus C-D. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Technical Performance of Insight BD: Accuracy and Repeatability on Breast Density Phantom | September 2023 - May 2024 | Evaluation of the volumetric breast density percentage produced by Insight BD on a standardized phantom, assessing measurement accuracy compared with the reference phantom values and repeatability across repeated acquisitions. |
| Concordance Between Insight BD BI-RADS Classification and Radiologist Assessment | September 2023 - May 2024 | Diagnostic agreement between Insight BD BI-RADS breast density classification and radiologist assessments. The outcome includes: * Percent agreement with the expert radiologist (primary reference). * Percent agreement with a non-expert radiologist to evaluate the tool's impact on less-experienced readers. |
| Recall Rate for Second-Level Examinations in Negative Mammographic Screens by BI-RADS Density | September 2023 - May 2024 | Proportion of women recalled for second-level diagnostic examinations among those with a negative screening mammogram, stratified by BI-RADS breast density categories (A, B, C, D) and by dichotomized density groups (A-B vs C-D). |
| Distribution of Breast Density by Menopausal Status, Hormonal Therapy, and Family History | September 2023 - May 2024 | Proportion of participants in each BI-RADS breast density category (A, B, C, D), and in dichotomized density groups (A-B vs C-D), stratified by: menopausal status (pre/post-menopause), use of hormonal therapy (yes/no), family history of breast cancer (yes/no). |
Countries
Italy